United States — Food and Drug Administration & Pete Hegseth

United States — Food and Drug Administration: The FDA proposed easing prescribing limits on testosterone products and removed a boxed warning on heart risks, facilitating broader use. These regulatory changes complement the military screening policy.

Pete Hegseth: As U.S. Defense Secretary, Hegseth announced and championed the mandatory testosterone screening policy, framing it as a readiness initiative. The policy reinforces his focus on military fitness and masculinity but has drawn political backlash.

United States — Food and Drug Administration: Mentioned in context of Harp's treatment; no market impact.

Pete Hegseth: Accompanied Trump on secret flight; no market impact.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.

Pete Hegseth: Pete Hegseth, the Defense Secretary, is pushing for rapid AI integration in the U.S. military and has clashed with Anthropic over safety concerns.